lactic acid has been researched along with Peripheral Nervous System Diseases in 12 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Peripheral Nervous System Diseases: Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The long-term effects of the sodium salt of dichloroacetic acid (DCA) were evaluated in four patients with mitochondrial encephalomyelopathy with lactic acidosis and stroke-like episodes (MELAS) carrying A3243G mutation." | 5.11 | Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. ( Goto, T; Momoi, MY; Mori, M; Saito, S; Yamagata, T, 2004) |
| " It frequently causes peripheral neuropathy and lipodystrophy and increases the risk of lactic acidosis and other high lactate syndromes." | 3.79 | Longitudinal lactate levels from routine point-of-care monitoring in adult Malawian antiretroviral therapy patients: associations with stavudine toxicities. ( Chagoma, N; Heyderman, RS; Kampira, E; Kaunda, S; Mallewa, J; Mukaka, M; Njalale, Y; van Oosterhout, JJ, 2013) |
| "Symptomatic hyperlactataemia and lactic acidosis (SHLA) are potentially life-threatening complications associated with stavudine (d4T), an antiretroviral therapy (ART) drug widely used in developing countries." | 3.76 | Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. ( Boulle, A; Meintjes, G; Osler, M; Rebe, K; Stead, D, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, ZL | 1 |
| Fan, ZY | 1 |
| Zhang, H | 1 |
| Li, ST | 1 |
| Yuan, H | 1 |
| Tong, JH | 1 |
| Chagoma, N | 1 |
| Mallewa, J | 1 |
| Kaunda, S | 1 |
| Njalale, Y | 1 |
| Kampira, E | 1 |
| Mukaka, M | 1 |
| Heyderman, RS | 1 |
| van Oosterhout, JJ | 1 |
| Santos, D | 1 |
| Giudetti, G | 1 |
| Micera, S | 1 |
| Navarro, X | 1 |
| Del Valle, J | 1 |
| Chabas, JF | 1 |
| Alluin, O | 1 |
| Rao, G | 1 |
| Garcia, S | 1 |
| Lavaut, MN | 1 |
| Legré, R | 1 |
| Magalon, G | 1 |
| Marqueste, T | 1 |
| Feron, F | 1 |
| Decherchi, P | 1 |
| Osler, M | 1 |
| Stead, D | 1 |
| Rebe, K | 1 |
| Meintjes, G | 1 |
| Boulle, A | 1 |
| Soderquist, RG | 1 |
| Sloane, EM | 1 |
| Loram, LC | 1 |
| Harrison, JA | 1 |
| Dengler, EC | 1 |
| Johnson, SM | 1 |
| Amer, LD | 1 |
| Young, CS | 1 |
| Lewis, MT | 1 |
| Poole, S | 1 |
| Frank, MG | 1 |
| Watkins, LR | 1 |
| Milligan, ED | 1 |
| Mahoney, MJ | 1 |
| Quigley, AF | 1 |
| Bulluss, KJ | 1 |
| Kyratzis, IL | 1 |
| Gilmore, K | 1 |
| Mysore, T | 1 |
| Schirmer, KS | 1 |
| Kennedy, EL | 1 |
| O'Shea, M | 1 |
| Truong, YB | 1 |
| Edwards, SL | 1 |
| Peeters, G | 1 |
| Herwig, P | 1 |
| Razal, JM | 1 |
| Campbell, TE | 1 |
| Lowes, KN | 1 |
| Higgins, MJ | 1 |
| Moulton, SE | 1 |
| Murphy, MA | 1 |
| Cook, MJ | 1 |
| Clark, GM | 1 |
| Wallace, GG | 1 |
| Kapsa, RM | 1 |
| Miura, T | 1 |
| Goto, M | 1 |
| Hosoya, N | 1 |
| Odawara, T | 1 |
| Kitamura, Y | 1 |
| Nakamura, T | 1 |
| Iwamoto, A | 1 |
| Mori, M | 1 |
| Yamagata, T | 1 |
| Goto, T | 1 |
| Saito, S | 1 |
| Momoi, MY | 1 |
| Walia, A | 1 |
| Thapa, BR | 1 |
| Kim, V | 1 |
| Stacpoole, PW | 1 |
| Furuya, H | 1 |
| Motomura, S | 1 |
| Kitaguchi, T | 1 |
| Ishimoto, S | 1 |
| Goto, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacotoxicology of Trichloroethylene Metabolites: Short-term Effect of DCA on in Vivo Tyrosine Catabolism and MAAI Expression[NCT00865514] | 2 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to Difficulty in obtaining the solution from the compounding pharmacies caused a two year delay in start-up; the funding ended prior to study completion.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for lactic acid and Peripheral Nervous System Diseases
| Article | Year |
|---|---|
The pharmacology of dichloroacetate.
Topics: Acetates; Amino Acids; Animals; Carbohydrate Metabolism; Chemical Phenomena; Chemistry, Physical; Di | 1989 |
1 trial available for lactic acid and Peripheral Nervous System Diseases
| Article | Year |
|---|---|
Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS.
Topics: Abdominal Pain; Administration, Oral; Adolescent; Chemical and Drug Induced Liver Injury; Child; Dic | 2004 |
10 other studies available for lactic acid and Peripheral Nervous System Diseases
| Article | Year |
|---|---|
Localized delivery of brain-derived neurotrophic factor from PLGA microspheres promotes peripheral nerve regeneration in rats.
Topics: Animals; Brain-Derived Neurotrophic Factor; Delayed-Action Preparations; Lactic Acid; Male; Mesenchy | 2022 |
Longitudinal lactate levels from routine point-of-care monitoring in adult Malawian antiretroviral therapy patients: associations with stavudine toxicities.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dru | 2013 |
Focal release of neurotrophic factors by biodegradable microspheres enhance motor and sensory axonal regeneration in vitro and in vivo.
Topics: Animals; Animals, Newborn; Biocompatible Materials; Enzyme-Linked Immunosorbent Assay; Female; Gangl | 2016 |
FK506 induces changes in muscle properties and promotes metabosensitive nerve fiber regeneration.
Topics: Animals; Disease Models, Animal; Growth Cones; Immunosuppressive Agents; Lactic Acid; Male; Muscle F | 2009 |
Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study.
Topics: Acidosis, Lactic; Adult; Alanine Transaminase; Anti-HIV Agents; Developing Countries; Drug Administr | 2010 |
Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration.
Topics: Animals; Behavior, Animal; Cells, Cultured; DNA; Gene Transfer Techniques; Genetic Therapy; Immunohi | 2010 |
Engineering a multimodal nerve conduit for repair of injured peripheral nerve.
Topics: Animals; Cell Movement; Lactic Acid; Male; Nerve Regeneration; Neural Prostheses; PC12 Cells; Periph | 2013 |
Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; DNA, Mitochondrial; Drug Therapy, Combination; Female; | 2003 |
Mitochondrial neuro-gastrointestinal encephalopathy syndrome.
Topics: Biopsy; Child; Diagnosis, Differential; Gastrointestinal Diseases; Humans; Intestinal Pseudo-Obstruc | 2006 |
[A case of Kearns-Sayre-Shy syndrome with neuropathy and high lactate content in CSF].
Topics: Humans; Kearns-Sayre Syndrome; Lactates; Lactic Acid; Male; Middle Aged; Ophthalmoplegia; Peripheral | 1985 |